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The development and implementation of an 
oxygen treatment solution for health facilities 
in low and middle-income countries
Background Oxygen reduces mortality from severe pneumonia 
and is a vital part of case management, but achieving reliable ac-
cess to oxygen is challenging in low and middle-income country 
(LMIC) settings. We developed and field tested two oxygen supply 
solutions suitable for the realities of LMIC health facilities.
Methods A Health Needs Assessment identified a technology gap 
preventing reliable oxygen supplies in Gambian hospitals. We used 
simultaneous engineering to develop two solutions: a Mains-Power 
Storage (Mains-PS) system consisting of an oxygen concentrator 
and batteries connected to mains power, and a Solar-Power Storage 
(Solar-PS) system (with batteries charged by photovoltaic panels) 
and evaluated them in health facilities in The Gambia and Fiji to 
assess reliability, usability and costs.
Results The Mains-PS system delivered the specified ≥82% ±3% 
oxygen concentration in 100% of 1-2 weekly measurements over 
12 months, which was available to 100% of hypoxaemic patients, 
and 100% of users rated ease-of-use as at least ‘good’ (90% very 
good or excellent). The Solar-PS system delivered ≥82% ±3% ox-
ygen concentration in 100% of 1-2 weekly measurements, was 
available to 100% of patients needing oxygen, and 100% of users 
rated ease-of-use at least very good.
Costs for the systems (in US dollars) were: PS$9519, Solar-PS 
standard version $20718. The of oxygen for a standardised 30-bed 
health facility using 1.7 million litres of oxygen per year was: for 
cylinders 3.2 cents (c)/L in The Gambia and 6.8 c/L in Fiji, for the 
PS system 1.2 c/L in both countries, and for the Solar-PS system 
1.5 c/L in both countries.
Conclusions The oxygen systems developed and tested delivered 
high-quality, reliable, cost-efficient oxygen in LMIC contexts, and 
were easy to operate. Reliable oxygen supplies are achievable in 
LMIC health facilities like those in The Gambia and Fiji.
Electronic supplementary material: 
The online version of this article contains supplementary material.
© 2020 The Author(s)
JoGH © 2020 ISGH
Acute respiratory infection (ARI), principally pneumonia, remains a 
leading cause of death in young children worldwide [1]. Case-manage-
ment of pneumonia is a key component of the WHO Integrated Man-
agement of Childhood Illness (IMCI) strategy and will remain integral 
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to efforts to reduce child mortality [2,3]. WHO guidelines for the management of pneumonia include 
the appropriate use of oxygen in addition to antibiotic therapy and general supportive care. Oxygen is 
needed to treat hypoxaemia, a life-threatening feature of severe pneumonia resulting from impaired lung 
function. Oxygen treatment reduces mortality from severe pneumonia in children substantially, and ox-
ygen is also a core treatment for other respiratory and non-respiratory severe childhood and adult diseas-
es, notably including COVID-19 [4-7].
Medical oxygen is in limited supply in low and middle-income countries (LMIC), a challenge that is exac-
erbated further by the current COVID-19 pandemic [6,8]. Oxygen is traditionally supplied in high-pres-
sure cylinders, which are expensive, logistically challenging, and often not available [9,10]. Oxygen con-
centrators provide an alternative to the high cost and logistical problems associated with oxygen cylinders 
[6,10,11]. Oxygen concentrators are not without limitations, however: maintenance is needed to maximise 
their life and, importantly, they need a reliable source of power, which is very often not available in LMIC 
health facilities or to the populations they serve [12,13]. A 2013 review of over 4000 health facilities in 
11 countries across sub-Saharan Africa found that only 28% had reliable electricity [14].
A Health Needs Assessment framework was used to address oxygen needs for health facilities in The 
Gambia [15,16]. A situational analysis showed that oxygen availability was inadequate to meet the needs 
in most health facilities [17]. An options analysis identified that, while oxygen concentrators had signifi-
cant advantages over cylinders, currently available solutions were not realistically able to meet the all the 
challenges of the context, including the need for reliable power [12]. A gap in technology needed to be 
addressed to reliably give patients and health systems the benefit of oxygen delivered through oxygen 
concentrators. The goal of this project was to address that gap.
The specific objectives were to develop and field test a concentrator-based oxygen system that would 
overcome the barriers of unreliable power and maintenance to supply oxygen reliably 24 hours a day, 
365 days a year. It was envisaged that continuity of supply would be achieved by combining concentra-
tor technology with power storage and, where needed, an off-grid power source such as solar photovol-
taic panels. We aimed to identify the most feasible system that could operate with limited or no mains 
power and limited maintenance in the target LMIC context, and in doing so we undertook field testing 
in facilities in both The Gambia and in Fiji.
METHODS
Health Needs Assessment framework
A Health Needs Assessment (HNA) framework is the overarching public health methodology we applied 
to define issues surrounding oxygen treatment, starting in The Gambia, and the options for improving 
it [15,16,18]. A gap analysis identified the need for a technical solution that would bring the benefits of 
oxygen concentrators to a context of typically unreliable power supply.
Technology development approach
Technology development for the project used ‘concurrent or simultaneous engineering’, an approach that 
considers all aspects of a project in parallel rather than in series, and which facilitates the efficient devel-
opment and uptake of new technology and in which product attributes are used to evaluate a product 
throughout the design process [19-21]. We ran experiments simultaneously testing hypotheses that were 
informing the final design in collaboration with our main suppliers, the end users and the research team.
Design specification
The design specification called for a system that was modular, designed to supply up to five children and 
installed in multiples where needed, able to deliver oxygen continuously, with a two-day electricity back-
up capacity (Appendix S1 in the Online Supplementary Document).
We developed and tested two systems: a mains-connected Power Storage (Mains-PS) system incorporat-
ing oxygen concentrator, batteries and electronic control components; and an off-grid Solar-PS system 
that incorporated an additional photovoltaic array and an online monitoring system. The systems were 
designed and modeled for performance and refined virtually before production of a prototype. Proto-
types were bench-tested to assess actual performance against modeled performance. Successful proto-
types were then trialed in the field.
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Initial development and piloting
The early development phase for a PS system was between 2009 and 2014, which involved design, 
bench-testing and pilot field testing in Basse Health Centre, a 25-bed facility with unreliable electricity 
serving the Upper River Region of The Gambia [9]. After an assessment of power availability at health fa-
cilities in The Gambia to better understand typical power interruption frequencies and durations, a pro-
totype backup power system, supplied by Dulas (UK), was developed and bench-tested at the Medical 
Research Council Unit, The Gambia (MRCG) [22]. The system consisted of gel sealed batteries, an in-
verter and a charger, with integrated surge protection. Bench-testing demonstrated that the system could 
provide oxygen 24 hours per day with as little as 4 hours of charging time, regardless of whether charging 
time was consecutive hours or dispersed throughout the day. Power interruptions of 2 hours or less had 
very little effect on the overall charge of the system. For all bench experiments, oxygen concentration 
was consistently within the required range (≥82% ±3%) regardless of the power situation (charging from 
grid or on battery power) [22]. The PS system was then installed at the Basse Health Centre in July 2011 
[23]. The PS system was wired to dedicated electrical sockets in the ward, where an Airsep New Life Elite 
oxygen concentrator (Caire Inc, USA) was connected. The downstream oxygen conduit connected to an 
Airsep Sureflow 5-flowmeter unit (Caire Inc, USA). Backup from a cylinder supply manifold outside the 
ward was also connected to the Sureflow and operated by an on-off connector switch. The pilot system 
functioned to specification, and based on lessons from the pilot period, the design was revised and the 
components were upgraded to harmonise systems across test sites.
Field testing
We formally field tested the final specification PS systems in paediatric wards at Basse Health Centre, 
Soma Health Centre and Farafenni Hospital (Figure 1) from July 2014 to June 2015. Soma Health Cen-
tre has 20 paediatric beds, no oxygen supply, electricity availability for 4-11 hours per day, and serves 
the Lower River Region of The Gambia; Farafenni Hospital, with 29 paediatric beds, an unreliable oxy-
gen supply, and power available for 20-23 hours per day, serves the North Bank Region of The Gambia. 
The Solar-PS system was developed in collaboration with Azimut 360 (Barcelona, Spain), and was field 
tested in Soma Health Centre and Farafenni Hospital (The Gambia), and in Nausori Health Centre, Suva, 
Fiji, between January 2016 and February 2017. Nausori Health Centre is a busy 6-bedded (child and 
adult) facility serving the periurban Rewa subdivision of Fiji, and was selected as the initial facility in Fiji 
for installation because of its high patient burden and its relative accessibility from Suva. Staff training in 
the detection of hypoxaemia and the use of the Mains-PS and Solar-PS systems was undertaken during 
implementation and refresher training conducted periodically during the test period.
Figure 1. PS system diagram (Panel A) and in situ Basse Health Centre (Panel B and 
Panel C). Panel A: PS system diagram Basse Health Centre. Panel B: PS system ox-
ygen concentrator connected to 5-outlet SureFlow (Chart Inc) unit. Panel C: PS 
system electronic control board and battery storage.
A B
C
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Evaluation approach
We measured the oxygen concentration produced by the systems, the availability of oxygen for patients, 
and the acceptability of the systems to clinical users (nurses and doctors). All admissions had pulse ox-
imetry done routinely during admission.
The success criteria for bench-testing of systems were:
Output ≥82% ± 3% oxygen concentration (the applicable ISO standard [24]) for >90% (acceptable >80%) 
of monitoring checks, measured at least daily by an oxygen analyser with <1% measurement error range.
The success criteria for the field testing of the systems were as follows:
a)  Output ≥82% ± 3% oxygen concentration for target >90% (acceptable level >80%) of 
monitoring checks, measured 1-2 weekly by an oxygen sensor with <1% measurement 
error range.
b)  Oxygen available from the systems for up to the number of hypoxaemic children the sys-
tem was specified to supply for target >90% (acceptable level >80%) of the time, mea-
sured by check sheet at admission and daily.
c)  Ease of use by actual health staff (rated at least ‘good’ on 5-point scale (poor, fair, good, 
very good, excellent) by target >80% (acceptable >60%) of users, measured by ques-
tionnaire.
The capital and running costs of the systems (comprising all components including concentrators) were 
measured and compared to the costs of equivalent oxygen delivery with locally available cylinder oxygen. 
Oxygen costs from the systems were modelled for two differently sized representative health facilities us-
ing a cost-modelling tool previously described [12].
Ethical approval for the study was given by the Gambia Government-MRC Joint Ethics Committee (SCC/
EC974), and field testing in Fiji approved and coordinated by the Fiji Ministry of Health and Medical 
Services.
RESULTS
Mains-Power Storage (Mains-PS) system
The specification for the Mains-PS system is shown in the Appendix. Bench test data showed that the 
system worked as specified and could be installed in less than one day. Field testing was carried out be-
tween July 2014 and February 2017; data are shown in Table 1, and the system in situ is shown in Fig-
ure 1. A median oxygen concentration of 92.5% (range 82.2%-95.4%) was generated from the system. 
An SpO
2
 < 90% was recorded on 1156 of 12863 (8.0%) children (<15 years old) presenting to the study 
facilities. Oxygen was available from the PS system in all of these instances (100%). Nineteen of 20 (95%) 
clinical staff users of the system rated its ease of use at least good, and 18/20 (90%) rated it very good or 
excellent (Table 2).
Table 1. Power storage (PS) system – oxygen concentration output at maximum flow (5 L/min), and availability of 
oxygen for clinical care
OutcOme measured Number/prOpOrtiON
Oxygen concentration Recordings (No.) 56
Oxygen concentration output, Median (range) 92.5% (82.2-95.4)
Proportion of recordings ≥82% ± 3% concentration 100%
Availability of oxygen to patients:
Pulse oximetry readings (No.) 12863
Pulse oximetry readings <90% SpO
2
 (No.) 1156
Pulse oximetry readings <90% for which oxygen was available, No. (%)* 1156 (100%)
SpO
2
 – peripheral capillary oxygen saturation
*Target 90%.
Oxygen solutions for LMICs
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Solar-Power Storage (Solar-PS) system
The specification for the Solar-PS system is shown in the Appendix. Bench test 
data showed that both the standard version (transported in several parts and as-
sembled on site) and trailer version (transported as an integrated unit towed by a 
vehicle) of the Solar-PS system worked as specified and that both versions could 
be installed in less than one day. Field testing data are shown in Table 3 and the 
system in situ is shown in Figure 2.
Field testing showed that the system produced a median oxygen concentration 
of 89.8% (range 88.0%-99.7%), above the specified minimum of ≥82% ± 3%. An 
SpO
2
 < 90% was recorded on 1974 of 13862 (14.3%) children (<15 years old) 
admitted to the study facilities. Oxygen was available from the Solar-PS system 
in all of these instances (100%). All (14/14) clinical staff users of the system rat-
ed its ease of use excellent (Table 4).
Table 2. Power storage (PS) system – 
ease of use by health staff (5-point scale, 
“Poor”, “Fair”, “Good”, “Very Good”, 
“Excellent”)
OutcOme measured Number/OutcOme
No. staff 20
No. rating “Poor” 0
No. rating “Fair” 1
No. rating “Good” 1
No. rating “Very Good” 10
No. rating “Excellent” 8
Median rating Very Good
%≥‘Good’ (Target >80%) 95
Figure 2. Solar-PS systems in the field. Panel A: Standard Solar-PS systems in situ in AFPRC Hospital, Farafenni, The Gambia. Panel 
B: Trailer Solar-PS system installed at Soma Health Centre, Soma, The Gambia.*Wheels were subsequently removed and fence erect-
ed to deter theft. Panel C: Trailer Solar-PS system supplying oxygen to a child in Soma Health Centre, Soma, The Gambia. *Photo-
graph used with permission of caregiver.
Table 3. Solar-power storage (PS) system – oxygen concentration output at maximum flow (5 L/min), and availabil-
ity of oxygen for clinical care
OxygeN cONceNtratiON OutcOme measured Number/prOpOrtiON
Recordings (No.) 38
Oxygen concentration output, Median (range) 89.8% (88.0-99.7)
Proportion of recordings ≥82% ± 3% concentration 100%
Availability of oxygen to patients:
Pulse oximetry readings (N) 13862
Pulse oximetry readings <90% SpO
2
 (No.) 1974
Pulse oximetry readings <90% for which oxygen was available, No. (%)* 1974 (100%)
SpO
2
 – peripheral capillary oxygen saturation
A
B
C
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Additionally, remote monitoring data were available for the Solar-PS 
system in Farafenni, which showed over a period of 360 days (from 9 
December 2015 to 4 December 2016) that power supply was available 
99.5% of the time and batteries were in general in a high state of charge 
(mean batteries minimum State of Charge:76%). Mean daily hours of 
use of the O2 concentrator was 16.7 hours per day (Figure 3).
Cost analysis
Equipment costs for the systems were (in US dollars) $9519 for the 
Mains-PS system and US$20 718 for the standard Solar-PS system, 
with the trailer-mounted version costing US$26 963 (Table 5). The 
cost of oxygen delivered from the systems, and compared with cyl-
inder-sourced supplies, are shown in Table 6. The total costs (capital 
and running costs) for a standardised paediatric facili-
ty of 15 beds and using 500 000 L of oxygen annually 
(calculated over 5 years) were estimated at US$5515 
for the Mains-PS system, US$7322 for the standard So-
lar-PS system and US$4815 for a cylinder supply with 
no leakage. We have found that leakage in the Gambi-
an context is common and often significant, and annu-
al cost at 10% leakage is estimated to be US$5350 while 
at 70% leakage is US$17 832. In Fiji the annual cost for 
this standardised paediatric facility of the PS system was 
US$5391, the Solar-PS system US$7322, and the cylin-
der cost US$10 068 with no leakage (US$11 187 at 10% 
leakage and US$37 289 at 70% leakage).
For a standard mixed adult-child facility using 1.5 mil-
lion litres of oxygen annually costs were estimated at 
US$5932 for the PS system, US$7566 for the Solar-PS 
system and US$16 006 for a cylinder supply with no leak-
age (US$17 785 at 10% leakage and $59 282 at 70% leakage). In Fiji the annual cost for this standardised 
mixed adult-child facility of the PS system was US$5755, the Solar-PS system US$7566, and the cylinder 
cost US$33 967 with no leakage (US$37 741 at 10% leakage and US$125 803 at 70% leakage).
Table 4. Solar-power storage (PS) system – ease of 
use by health staff in participating facilities (5-point 
scale, “Poor”, “Fair”, “Good”, “Very Good”, “Excel-
lent”), December 2016*
OutcOme measured Number/OutcOme
No. staff 15
No. rating ‘Poor’ 0
No. rating ‘Fair’ 0
No. rating ‘Good’ 0
No. rating ‘Very Good’ 0
No. rating ‘Excellent’ 15
Median rating Excellent
%≥‘Good’ (Target >80%) 100
*Not yet administered at Nausori Fiji at report date.
Figure 3. Daily hours of usage of Solar PS oxygen system at Farafen-
ni Hospital during formal 12-month monitoring (December 2015 
to November 2016).
Table 5. Item capital costs and running costs (US$)* for PS system (including concentrator) supply, solar-PS system (including con-
centrator) supply, oxygen concentrator powered from mains supply alone, and oxygen cylinder supply
ps sOlar-ps† cyliNder cONceNtratOr (maiNs pOwered)
Capital Concentrators* 675 675 675
Patient delivery-associated equip-
ment
495 495 187 495
Additional equipment 8349 19 548
Total equipment cost 9519 20 718 187 1170
Transport Teknon to site 265 265 133
Shipping 3947 3925 300
Installation 484 484 162
Operating expenses Electricity unit cost (per kWh) 22.2 c Gambia, 15.8 c Fiji 0
22.2 c Gambia, 
15.8 c Fiji
Maintenance 2105 1585 842
Cylinder refill Gambia 44.52
Fiji 51.48
Cylinder rent pa Gambia 0
Fiji 1007.28
Cylinder transport (per cylinder) 11
PS – power storage; c – cents
*Exchange rates: 1US$ = Euro0.853 / GBP0.753.
†Standard Solar-PS system. Total equipment costs for the trailer-mounted version were US$26 963.
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DISCUSSION
We found that the two systems developed to address the challenges of achieving a reliable oxygen sup-
ply in LMIC health facilities with poor power availability, the Mains-Power-Storage (Mains-PS) system 
and the Solar-Power storage (Solar-PS) system, delivered good quality oxygen reliably in both Gambian 
and Fijian settings, and were rated as very user-friendly for staff. These two systems, which use readi-
ly available components and are able to be assembled without specialist facilities or expertise, included 
mains-connected battery power-storage for the Mains-PS system and off-grid battery storage connected to 
solar power-generating panels for the Solar-PS system. We also found that the costs for oxygen were sim-
ilar or lower than the existing cylinder supply systems in modelled standardised facilities relevant to the 
settings of the study. The specifically solar components of the standard Solar-PS system made it around 
one-third more expensive than the Mains-PS system.
User satisfaction with the Mains-PS and Solar-PS systems was high, and users reported that they general-
ly preferred the new systems to the old cylinder-based supply. The main reasons for this preference were 
that they did not worry about running out of oxygen, they did not have the logistical complications and 
transactional costs of procurement, they did not need to move large cylinders, and they were less wor-
ried about cylinders falling over and causing a hazard. Training was important to familiarise the staff with 
the new systems, and refresher training was undertaken periodically to support this. In Fiji users report-
ed that they sometimes found the maximum flow of 5 LPM from the Airsep Elite concentrator used in 
the systems limiting when treating very sick adults. The usability of oxygen concentrators has also been 
found to be favourable in other LMIC settings [6,25].
Modelled costs in the smaller-use standardised child facility using PS and Solar-PS systems in the Gam-
bian context were similar to those for a cylinder-based supply, assuming no cylinder leakage, while the 
costs in the Fijian context were around half those of a cylinder-based supply. The oxygen costs from test 
systems in a modelled larger-use mixed age facility were around one-half to one-third that of a cylin-
der-based system in The Gambia, and one-quarter to one-sixth the cost in Fiji. Where mains power is 
reliable oxygen costs using concentrators alone is around one-third of that from the PS and Solar-PS sys-
tems. This becomes highly relevant as wider programmes in a mix of facilities varying in size and power 
reliability are implemented, and overall cost-efficiency is enhanced.
One barrier to implementation of these and similar systems in LMIC health systems is that they have high 
initial up-front capital costs. Despite the cost advantages of these systems overall, driven by low running 
costs, the reorientation of health budgets in LMICs to take advantage of these potential efficiencies can 
Table 6. Overall oxygen costs (US$) for a standardised paediatric ward* and a standardised all-age health facility† (costs in parenthe-
ses are costs without shipping costs included)
ps sOlar-ps3 cONceNtratOr cyliNder
No leakage 10% leakage 70% leakage
Standardised 
paediatric facility 
using 0.5 mL/year
Cost per litre 
oxygen
Gambia 0.0110 (0.0100) 0.0146 (0.0131) 0.0035 0.0096 0.0107 0.0321
Fiji 0.0108 (0.0092) 0.0146 (0.0131) 0.0033 0.0201 0.0224 0.0755
Cost per 
annum
Gambia 5515 (4725.6) 7322 (6533.4) 1762 4815 5350 17832
Fiji 5391 (4601.6) 7322 (6533.4) 1638 10068 11187 37289
Standardised all-age 
facility using 1.7 mL/
year
Cost per litre 
Oxygen
Gambia 0.0119 (0.0103) 0.0151 (0.0135) 0.0044 0.0320 0.0356 0.1067
Fiji 0.0115 (0.0099) 0.0151 (0.0135) 0.0040 0.0679 0.0755 0.2264
Cost per 
annum
Gambia 5932 (5142.6) 7566 (6767.4) 2179.0 16006 17785 59282
Fiji 5755 (4965.6) 7566 (6767.4) 2002 33967 37741 125803
PS – power storage, Solar-PS – solar-power storage
* Standardised paediatric ward used here comprises 15 beds, 500 000L of oxygen used annually, 1286 patients/years (a bed occupancy of approxi-
mately 100% across a year – a moderate-high occupancy facility), a 6% prevalence of hypoxemia amongst admissions, and average length of oxygen 
treatment of 3 days at an average 1.5 L/min flow of oxygen, a total average hospital stay of 5 days, and 5556 oxygen concentrator hours of running 
annually shared between 2 concentrators (the regulation number for a facility this size, run from one PS or Solar-PS system) with a lifespan of 5 years.
† Standardised all-age facility used here comprises 30 beds, 1.7 mL of oxygen used annually, an average bed occupancy of 67% (reflecting a moderate 
occupancy facility), half of admissions being children and half adults, a 6% prevalence of hypoxaemia amongst children admitted and a 9% preva-
lence of hypoxaemia among adults, and average length of oxygen treatment of 3 days at an average 1.5 L/min flow of oxygen for children and 5 L/
min for adults, a total average hospital stay of 5 days, and 7906 oxygen concentrator hours of running annually shared between 3 concentrators (the 
regulation number for a facility this size, run from one PS or Solar-PS system) with a lifespan of 5 years.
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be challenging in practice, and committed leadership and advocacy is required to implement them. Do-
nors can help overcome the hurdle of high capital costs, and often prefer their support to be directed to 
easily measurable capital items rather than to ongoing running costs. The systems reported here match 
such donor preferences well.
High use of oxygen tends to increase the comparative cost-efficiency of concentrator-sourced delivery and 
conversely low use decreases it. The standard facilities used for estimates attempt to reflect different levels 
of use; however, these standardised facilities involve assumptions that will not apply in all cases. Where 
a facility uses higher flows of oxygen for shorter periods the estimated costs of oxygen by volume will be 
lower for the concentrator-based systems than reported here as the cost-efficiency of concentrators in-
creases with increasing output flow. Additionally, our estimates for the standardised facilities assume that 
one patient at a time is being treated, despite the capacity to treat up to five simultaneously, which will 
result in higher estimated costs for oxygen from concentrator-based systems. Leakage of oxygen cylinders 
is routinely observed in our experience in LMIC settings, sometimes at high levels [12]. The compari-
sons reported assume no leakage from oxygen cylinders, so may underestimate cylinder costs. Underes-
timation of cylinder costs may also have resulted from no maintenance costs being included for cylinders 
and related equipment, and, in Fiji, from the comparatively low cylinder transport costs associated with 
Nausori Health Centre’s high accessibility compared to most locations in Fiji. The cost-efficiency of oxy-
gen delivery methods will depend on the particulars of the facility’s oxygen demand; nevertheless, there 
is evidence of cost-efficiency from concentrator-based systems in this study.
The health facility staff at the study sites were encouraged to maintain a backup cylinder supply in case 
there should be problems with the Teknon systems. While these systems proved reliable in the course of 
field testing, no system is fail-safe and contingencies remain important in all aspects of health systems, 
which in this case also include trained technicians and adequate spare parts. Cylinders can also meet 
some needs that the concentrators used in the systems do not, for instance high flow delivery of oxygen 
(>5LPM), oxygen for transport to a referral facility, and the needs of surgical anaesthesia. Higher flow con-
centrators, delivering up to 10L/min flow, are available and have been used with success in LMIC settings 
and can be coupled with the systems reported here [26]. This is relevant particularly for the treatment 
of adults, who are more likely to require flows above 5 L/min. The Teknon systems can run such con-
centrators, which have a higher power requirement, and the practical implication of doing so is simply 
that the system will run from batteries alone for less than the specified two days, which in many settings 
is not a practical impediment to providing reliable supplies. Concentrators can also be used to support 
purpose-designed anaesthetic equipment [27].
The logistical capability to supply cylinders reliably, which is challenging, becomes correspondingly 
more difficult with increasing remoteness. Poor power availability and quality is a reality in many LMIC 
health facilities, and becomes more likely the more remote a facility is.[14] Universal access to energy by 
2030, UN Sustainable Development Goal 7 [3], highlights the importance of electricity, and the WHO 
has stressed the importance of this for health facilities and the importance of solar solutions to achieve 
the goal [28,29]. There is more than one approach that can be taken to overcoming these barriers using 
oxygen concentrators. One is to power the concentrators alone as a core essential medicine, and that is 
the approach we have taken: while the systems can bear the running of limited other equipment, such as 
a pulse oximeter and a light, their core aim is to support oxygen supply. Another approach is to power 
a health facility, or a range of ‘essential’ equipment, and this is an approach being tested in West Africa 
[30]. Nevertheless, the decision on scope of systems is important and has implications for deliverabili-
ty, robustness and sustainability. In settings where power is scarce the risks of power being inappropri-
ately diverted to non-core applications is high, and dedicating a power source to one essential piece of 
equipment using connections not compatible with other equipment reduces this risk. An example of this 
approach is the solar vaccine fridges used widely in LMICs [31]. Similarly, the Teknon systems are de-
signed for settings in which infrastructure cannot reliably run concentrators connected to mains power 
and where the running of a range of equipment is a “bridge too far”.
A number of directions for future development are apparent. The Teknon specifications can serve as a 
platform for further development for more specific clinical and geographical applications, and as suitable 
alternative components and technology become available. The stipulation that power storage capacity 
should allow for 2 days running without the need for recharge could be reduced to make the size and 
cost of the systems smaller, and their portability, and consequent geographical reach, potentially greater. 
Broader developments in technology that may support the wider roll-out of oxygen systems such as Te-
knon to reach the least accessible patients include the development of a robust direct current (DC) oxy-
Oxygen solutions for LMICs
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gen concentrator, which would reduce the power requirements, and therefore size and potentially cost, 
of a system, and advances in battery technology to reduce the size and costs of units needed. A further 
area for exploration is the inclusion of a low-pressure oxygen storage component, which might have the 
advantage of reducing the power storage capacity required and increasing the efficiency of use of the con-
centrator, with the potential disadvantage of a larger footprint and a more complex system, and there has 
been recent work in this area [32,33]. Reducing mortality and morbidity from hypoxaemic illness is not 
simply about having a reliable oxygen supply available, but also about patients having access to health 
services, and then being diagnosed and treated appropriately [34]. Nevertheless, a reliable oxygen sup-
ply is the vital starting point.
Oxygen has traditionally been in the “too hard basket” despite it being included in WHO treatment guide-
lines and Model List of Essential Medicines, but this is no longer the case. It is vital that oxygen be made 
available to the children, and the adults, that need it. This study shows that the Teknon systems, the spec-
ifications of which are made available here, are one means to achieving this aim.
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